CJC 1295 + Ipamorelin (No DAC) (5mg/5mg)

Shop high-purity CJC 1295 + Ipamorelin 5mg/5mg (No DAC) at Eternal Peptides, the industry leader in verified research compounds. This synergistic blend is synthesized to a standard of ≥99% purity, with every batch supported by independent third-party COAs from Janoshik. Our CJC-1295 and Ipamorelin combination is designed for researchers studying natural growth hormone pulsatility and endocrine signaling. Order today for fast, secure US shipping and free Priority delivery on all orders over $200

What is the CJC 1295 + Ipamorelin (No DAC) Blend?

CJC + Ipamorelin (No DAC) is a synthetic peptide combination composed of CJC 1295 and ipamorelin, a selective growth hormone–releasing peptide.

“No DAC” means the CJC 1295 molecule does not include the drug affinity complex (DAC) that normally prolongs its half-life. As such, the “no DAC” version is short-acting and therefore useful in research models that require natural, pulsatile growth hormone release rather than sustained exposure.

CJC-1295 (No DAC) is a modified analogue of growth hormone–releasing hormone (GHRH), typically consisting of 29 amino acids, while ipamorelin is a short pentapeptide classified as a ghrelin mimetic. Both peptides are fully synthetic and were developed to study regulated growth hormone signaling rather than being direct endogenous fragments.

In the scientific literature, this peptide pairing is primarily investigated for its role in growth hormone pulsatility, endocrine signaling, and downstream metabolic and tissue-related processes.

Most published findings derive from in vitro experiments and animal models, where researchers examine hormonal regulation, receptor selectivity, and signaling dynamics.

Mechanistically, CJC-1295 (No DAC) interacts with the GHRH receptor, while ipamorelin selectively activates the ghrelin (GHS-R1a) receptor, together supporting coordinated stimulation of growth hormone release pathways. However, controlled human clinical evidence is limited, so current findings are entirely preclinical research context.

How CJC-1295 (No DAC) + Ipamorelin Blend Works

The CJC-1295 + Ipamorelin blend (No DAC) is studied as a dual-pathway peptide system that modulates growth hormone (GH) release through complementary receptor mechanisms. Current mechanistic understanding is derived primarily from in vitro research and animal models, where these peptides are examined for their coordinated effects on endocrine signaling rather than direct tissue action.

GHRH Receptor Activation (CJC-1295 No DAC)

CJC-1295 (No DAC) is a modified analogue of growth hormone–releasing hormone that binds to the GHRH receptor located on pituitary somatotroph cells. Preclinical studies show that this interaction enhances endogenous GH pulse amplitude while maintaining physiological release patterns.

Unlike DAC-modified variants, the No DAC form has a shorter half-life, making it useful for studying acute receptor signaling dynamics.

This mechanism matters in research because GH pulsatility influences downstream signaling cascades involved in cellular growth regulation and metabolic balance. Investigators often use this model to explore how controlled GH stimulation affects secondary mediators such as insulin-like growth factor 1 (IGF-1).

Ghrelin (GHS-R1a) Receptor Selectivity (Ipamorelin)

Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist designed to stimulate GH release with minimal activity at other hormone-related receptors[2]. In preclinical models, ipamorelin demonstrates a high degree of specificity, avoiding significant activation of pathways associated with cortisol or prolactin secretion.

This selectivity is important in experimental settings because it allows researchers to isolate GH-related effects without broad endocrine disruption. As a result, ipamorelin is commonly studied to better understand receptor-driven GH signaling and its downstream cellular effects under controlled conditions.

Synergistic Growth Hormone Pulsatility

When studied together, CJC-1295 (No DAC) and ipamorelin demonstrate complementary receptor engagement—one acting through the GHRH receptor and the other through the ghrelin receptor[3]. Preclinical research suggests that this dual stimulation produces more consistent and physiologically patterned GH pulses than either peptide alone.

This synergy is relevant because natural GH secretion is pulsatile rather than continuous. Research models use this combination to explore how synchronized receptor activation may influence signal timing, receptor sensitivity, and hormonal feedback loops involved in tissue maintenance and cellular turnover.

Downstream IGF-1 and Cellular Signaling Pathways

In animal and in vitro studies, increased GH release stimulated by this peptide combination is associated with downstream modulation of IGF-1 and related intracellular signaling pathways, including those involved in protein synthesis and cellular metabolism[4].

These effects are indirect and mediated through endogenous hormone cascades rather than direct peptide action on tissues.

Researchers study these pathways to better understand how endocrine signals influence cellular environments associated with growth regulation and tissue structure. However, controlled human clinical evidence remains limited, and these findings should be interpreted strictly within a preclinical research framework.

Research Value: CJC-1295 (No DAC) + Ipamorelin Blend

CJC-1295 (No DAC) and Ipamorelin are often studied together in preclinical research due to their complementary roles in growth hormone–related signaling. 

Research on their combined use emphasizes how dual-pathway engagement may better replicate endogenous growth hormone pulse patterns. Key research considerations include:

• Support for tissue repair and regeneration through modulation of growth hormone–dependent pathways.
• Influence on metabolism and protein synthesis, reflecting growth hormone–associated activity in experimental models.
• Potential modulation of muscle and connective tissue adaptation, studied in in vitro and animal contexts.
• Regulation of systemic signaling patterns, showing improved mimicry of natural growth hormone pulse dynamics.

These insights are intended strictly for controlled research contexts and should not be extrapolated to human clinical use.

CJC-1295 (No DAC) + Ipamorelin: Peptide Characteristics

Molecular Formula: C165H269N47O46(CJC-1295) & C38H49N9O5(Ipamorelin)

Batch: EP-250602-CI5

Handling & Storage Guidelines

The CJC-1295 (No DAC) + Ipamorelin blend is supplied in lyophilized powder form, which can be stored at –4°F to 39°F (–20°C to 4°C) in a dry environment, protected from light and moisture to maintain stability. Keep vials sealed until use and avoid prolonged exposure to ambient air.

For reconstitution, allow the vial to reach room temperature before adding sterile or bacteriostatic water using aseptic laboratory technique. Buy bacteriostatic water right here on Eternal Peptides for best results.

Gently introduce the solvent along the vial wall and swirl lightly; do not shake, as agitation may degrade peptide structure. Once reconstituted, the solution should be stored at 36°F to 46°F (2°C to 8°C) and used within standard laboratory-defined timeframes.

To minimize degradation, aliquot reconstituted solutions into smaller volumes where feasible and avoid repeated freeze–thaw cycles. For longer-term storage, aliquots may be frozen at –4°F (–20°C) or lower, following institutional protocols. All handling should comply with laboratory safety standards, proper labeling practices, and institutional research guidelines.

COA / Quality Assurance

In keeping with our stringent quality standards, every lot of CJC-1295 (No DAC) + Ipamorelin blend supplied by Eternal Peptides is accompanied by a lot-specific Certificate of Analysis (COA) to support transparency, traceability, and reproducible research.

COAs are provided by independent third-party laboratories after stringent testing, such as trusted testing facility Janoshik Analytical for the most objective verification of product quality.

These labs use analytical methods such as high-performance liquid chromatography (HPLC) and/or mass spectrometry, along with quantitative purity analysis confirming ≥99% peptide content. Where applicable, sterility testing and endotoxin level assessments are performed to verify suitability for controlled laboratory environments. COAs also include recommended storage conditions to help maintain peptide stability throughout handling and use.

Legal / Regulatory Disclaimer

Eternal Peptides supplies CJC-1295 (No DAC) + Ipamorelin blend strictly for laboratory research use only. This product is not approved for human or veterinary use and is not intended for clinical administration, therapeutic applications, diagnostic procedures, or consumption of any kind.

The safety, efficacy, and pharmacological effects of this peptide combination in humans have not been established through controlled clinical trials.

As the buyer/users, you are solely responsible for ensuring compliance with all applicable local, state, and federal laws, as well as institutional policies governing research chemicals and biosafety practices. Any misrepresentation of the intended research-only use of this product may result in regulatory action or legal consequences.

Scientific References

1. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7.

https://pubmed.ncbi.nlm.nih.gov/17018654/ 

2. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61.

https://pubmed.ncbi.nlm.nih.gov/9849822/ 

3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805.

https://pubmed.ncbi.nlm.nih.gov/16352683/ 

4. Al-Samerria S, Radovick S. The Role of Insulin-like Growth Factor-1 (IGF-1) in the Control of Neuroendocrine Regulation of Growth. Cells. 2021 Oct 5;10(10):2664.

https://pmc.ncbi.nlm.nih.gov/articles/PMC8534318/